RxDoctor Payments Data

Cynthia Calixte, MD

Family Medicine · Salisbury, MDNPI 1528300100

Payments from drug & device makers

$2,376in general payments, 2019–2025

Across 96 payments — averaging $24.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$224
  • Lilly USA, LLC$205
  • Amgen$178
  • Pfizer$176
  • Abbott$175
  • GSK$146
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$2,376100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,376 in reported general payments places this provider in the 80th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$57,740
Medicare patients
218
Services billed
963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate20$22,208
EliquisApixaban16$16,982
TrulicityDulaglutide13$12,981
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$11,286
JardianceEmpagliflozin14$11,153
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl46$8,322
TradjentaLinagliptin15$7,660
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$2,509
Potassium Chloride58$1,839
Ventolin HfaAlbuterol Sulfate13$1,816
Atorvastatin Calcium87$1,576
Amlodipine Besylate135$841
Ultra-Fine Short Pen NeedlePen Needle, Diabetic11$730
Losartan Potassium72$707
Albuterol Sulfate HfaAlbuterol Sulfate27$625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$12$22,20820 claims
Boehringer IngelheimJardiance, Tradjenta$21$18,81229 claims
PfizerEliquis$176$16,98216 claims
Lilly USA, LLCTrulicity$205$12,98113 claims
GSKTrelegy Ellipta$146$11,28612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →